These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 19329355)

  • 1. Resistance to antiretrovirals in HIV-infected pregnant women.
    Weinberg A; Forster-Harwood J; McFarland EJ; Pappas J; Davies JK; Kinzie K; Barr EA; Paul SM; Salbenblatt CR; Soda E; Vazquez A; Levin MJ
    J Clin Virol; 2009 May; 45(1):39-42. PubMed ID: 19329355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
    Bassetti D; Cargnel A
    Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
    PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
    Han J; Wang L; Jiang Y; Zhang Q; Fang L; Yao J; Wang Q
    Int J STD AIDS; 2009 Apr; 20(4):249-54. PubMed ID: 19304969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
    AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.
    Duran AS; Losso MH; Salomón H; Harris DR; Pampuro S; Soto-Ramirez LE; Duarte G; de Souza RS; Read JS;
    AIDS; 2007 Jan; 21(2):199-205. PubMed ID: 17197811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of HIV-1 drug resistance in antiretroviral-naive pregnant Thai women.
    Auswinporn S; Jenwitheesuk E; Panburana P; Sirinavin S; Vibhagool A; Chantratita W
    Southeast Asian J Trop Med Public Health; 2002 Dec; 33(4):818-21. PubMed ID: 12757232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
    Dao H; Mofenson LM; Ekpini R; Gilks CF; Barnhart M; Bolu O; Shaffer N
    Am J Obstet Gynecol; 2007 Sep; 197(3 Suppl):S42-55. PubMed ID: 17825650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
    Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
    J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1.
    Panburana P; Sirinavin S; Phuapradit W; Vibhagool A; Chantratita W
    Am J Obstet Gynecol; 2004 Mar; 190(3):803-8. PubMed ID: 15042018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines.
    Read P; Costelloe S; Mullen J; O'Shea S; Lyons F; Hay P; Welch J; Larbalestier N; Taylor G; de Ruiter A
    HIV Med; 2008 Aug; 9(7):448-51. PubMed ID: 18840150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
    Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites.
    Read JS; Cahn P; Losso M; Pinto J; Joao E; Duarte G; Cardoso E; Freimanis-Hance L; Stoszek SK;
    Obstet Gynecol; 2007 Jun; 109(6):1358-67. PubMed ID: 17540808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapartum zidovudine infusion alone failed to reduce both maternal HIV-1 viral load and HIV-1 infection in infant.
    Limpongsanurak S; Thaithumyanon P; Thisyakorn U; Ruxrungtham K; Chaithongwongwatthana S; Kongsin P; Tarounotai U; Chantheptaewan N; Triratwerapong T; Ubolyam S; Phanuphak P
    J Med Assoc Thai; 2001 May; 84(5):611-6. PubMed ID: 11560207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance.
    Gingelmaier A; Eberle J; Kost BP; Bogner JR; Hofmann J; Weissenbacher T; Kästner R; Friese K; Weizsaecker K
    Clin Infect Dis; 2010 Mar; 50(6):890-4. PubMed ID: 20166821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
    Dabis F; Bequet L; Ekouevi DK; Viho I; Rouet F; Horo A; Sakarovitch C; Becquet R; Fassinou P; Dequae-Merchadou L; Welffens-Ekra C; Rouzioux C; Leroy V;
    AIDS; 2005 Feb; 19(3):309-18. PubMed ID: 15718842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Pérez H; Vignoles M; Laufer N; Gómez A; Coll P; Lottner J; Rolón M; Salomón H; Cahn P
    Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
    Manavi K; McDonald A; Al-Sharqui A
    AIDS; 2007 Mar; 21(5):643-5. PubMed ID: 17314527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.